Darwin Qidian Biopharmaceutical

Darwin Qidian Biopharmaceutical, also known as Darwin Biotech, is a clinical-stage Chinese biotechnology company specializing in neural repair and regenerative medicine. The company utilizes a proprietary Mesenchymal Stem Cell (MSC)-derived protein complex platform to develop cell-free therapeutic candidates that activate intrinsic multi-pathway repair mechanisms. Its lead program, ALT001, is a protein complex therapy currently in Phase 1 clinical trials for indications such as Amyotrophic Lateral Sclerosis (ALS) and ischemic stroke, with additional studies in osteoarthritis. Darwin Qidian also explores innovative drug delivery technologies, including a partnership for microcrystal patch-based GLP-1 products for metabolic diseases. As a subsidiary of Beijing Darwin Cell Biotechnology, the company maintains a strong R&D and manufacturing presence in Beijing and Hubei to support its pipeline of neural repair therapeutics.